AERI News and Press, Aerie Pharmaceuticals Inc. From 03/18/22

Aerie Pharmaceuticals (NASDAQ:AERI) has appointed Peter F. Lang as Chief Financial Officer, effective March 18, 2022. “I am pleased to welcome Peter to our leadership team,” said Raj Kannan, Chief Executive Officer. “His extensive experience in investment bankin...

Finance executive with a successful track record in capital creation, deployment, and optimization Brings breadth of finance, strategy and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, dev...

Gainers: Inspirato (NASDAQ:ISPO) +48%. KAR Auction Services (NYSE:KAR) +40%. Farfetch (NYSE:FTCH) +39%. CarGurus (NASDAQ:CARG) +36%. Aerie (NASDAQ:AERI) +28%. IronNet (NYSE:IRNT) +26%. Nymox (NASDAQ:NYMX) +26%. Block (NYSE:SQ) +24%. Schrodinger (NASDAQ:SDGR) +21%. Paramount Group (NYSE:PGRE) ...

Aerie Pharmaceuticals (AERI +27.0%) is trading sharply higher in morning hours to record the biggest intraday gain since 2017 after the commercial-stage pharma company reported better-than-expected financials for Q4 2021 with quarterly net income for the first time in its history. Q4 202...

Gainers: Aerie Pharmaceuticals (NASDAQ:AERI) +25%. Schrodinger (NASDAQ:SDGR) +17%. MDxHealth (NASDAQ:MDXH) +16%. Lantheus (NASDAQ:LNTH) +13%. Tabula Rasa HealthCare (NASDAQ:TRHC) +13%. Losers: Baudax Bio BXRX -55%. The Joint (NASDAQ:JYNT) -15%. Biohaven...

Aerie Pharmaceuticals, Inc. (AERI) Q4 2021 Earnings Conference Call February 24, 2022, 17:00 ET Company Participants Hans Vitzthum - LifeSci Advisors Raj Kannan - CEO & Director Michelle Senchyna - Head, Clinical Development and Medical Affairs Jeffrey Calabrese - Director, Accounting Con...

Aerie Pharmaceuticals press release (NASDAQ:AERI): Q4 Non-GAAP EPS of $1.09 beats by $1.77. Revenue of $114.7M (+364.4% Y/Y) beats by $83.54M. Outlook: Glaucoma franchise net product revenues: target is $130 million to $140 million, up 16% to 25% versus 2021 For further details see: ...

2021 Glaucoma Franchise Net Revenues of $112.1 Million, an Increase of 35% over 2020 Fourth Quarter Glaucoma Franchise Net Revenues of $32.7 Million, up 11% From Third Quarter Guidance of $130 Million to $140 Million in 2022 Glaucoma Franchise Forecasted Net Revenues, ...

Aerie Pharmaceuticals (NASDAQ:AERI) said Gary Sternberg will join the company as chief medical officer, effective Mar. 1. Sternberg, an ophthalmologist fellowship trained in cornea and external diseases, joins AERI from RainBio, where he served as acting CEO. Late last year, AERI had nam...

Fellowship-trained Ophthalmologist and well-rounded biopharmaceutical executive b rings breadth of clinical development, medical affairs, strategy, and business development experience Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the dis...